PRA International, Inc. and IntrinsiQ Research, Inc. Enter Exclusive Agreement for Oncology Patient Treatment Data
RESTON, Va., March 19 /PRNewswire-FirstCall/ -- PRA International , a leading global clinical research organization, today announced that it has entered into an exclusive licensing agreement with IntrinsiQ Research for use of the company's Intellidose electronic medical record software used to manage oncology patients in the United States. IntrinsiQ Research collects real-time, longitudinal data on more than 45,000 patient treatments for nearly every type of cancer each month from over 600 oncology physicians. The data can be used to precisely forecast patient recruitment, thus accelerating the pace of clinical trials.
"Access to the IntrinsiQ Research data, combined with our recently announced alliance with US Oncology, reinforces our leadership position in oncology clinical research," said Kent Thoelke, Senior Vice President, Therapeutic Expertise, at PRA. "The most critical issue today in oncology drug development is the ability to determine the available patient population for any specific tumor type. PRA is using the data from IntrinsiQ Research to accurately predict patient enrollment for clinical trials in oncology and we have already demonstrated the benefits to several sponsors by exceeding their expectations for patient recruitment timelines and budgets."
The IntrinsiQ data includes detailed information on demographics, tumor type, stage of disease, previous treatment, current anticancer regimens, concomitant medication, laboratory measurements, scans, response data, time to progression, and other key factors. IntrinsiQ Research treatment data are regularly validated and thereby are a representative sample of oncology patients in the United States.
"IntrinsiQ's oncology data is the established industry benchmark, in use by 90 percent of the pharmaceutical companies in the US, as well as industry analysts. This agreement with PRA allows us to extend our leadership position into the contract research space," said Jeff Forringer, General Manager of IntrinsiQ's pharmaceutical division. "Through the use of our treatment data, PRA will be able to help pharmaceutical companies plan more efficient oncology clinical trials. Ultimately, this will mean bringing new medicines to market faster and improving patient care."
Dr. Monika Pietrek, Executive Vice President, Scientific & Medical Affairs at PRA, added: "One of PRA's key growth strategies is to 'lead with science' and this agreement with IntrinsiQ Research demonstrates our commitment to differentiate ourselves with our therapeutic expertise."
About PRA International
PRA International is a leading global clinical development organization, with over 2,700 employees working from offices in North America, Europe, Asia, South America, Africa, and Australia. PRA delivers services to its clients through a unique approach called Project Assurance(R), which represents the Company's commitment to reliable service delivery, program-level therapeutic expertise, easy, global access to knowledge and involved senior management. To learn more about PRA International, please visit http://www.prainternational.com or call our World Headquarters at +1 (703) 464-6300.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements that are subject to risks and uncertainties relating to PRA International's future financial and business performance, as well as any other predictive statements that depend on future events or conditions, or that include words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "may," "will," "estimate" or similar expressions of futurity. You should not place undue reliance on any forward-looking statements, which represent the company's statements only as of the date of this news release and are not intended to give any assurance as to actual future events. Factors that might cause future events to differ include: our ability to successfully implement the IntrinsiQ Research data into our clinical trials and provide benefits to our sponsors; the ongoing need for early and late phase drug development services; project cancellations and timing issues; our ability to attract and retain qualified personnel; our ability to continue providing our services effectively, including the quality or accuracy of the data or reports provided and our ability to meet agreed- upon schedules; the ability and willingness of our clients to continue to spend on research and development at rates comparable to or greater than historical levels; trends or events affecting the CRO industry and the demand for CRO services; government regulation, including regulatory standards applicable to CRO services; evolving industry standards and technological changes; and general business and economic conditions. Events relating to PRA International could differ materially from those anticipated in these forward- looking statements. Although these statements are based upon assumptions company management believes to be reasonable based upon available information, they are subject to the foregoing risks and uncertainties as well as those described more fully in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our annual report on Form 10-K. This document can be accessed in the SEC's EDGAR database found at http://www.sec.gov. Please note that PRA International assumes no obligation to update any of the forward-looking statements in this release, except as required by applicable securities laws.PRA International
CONTACT: John Lewis, Director, Marketing & Public Relations of PRAInternational, +1-703-464-6338, email@example.com; or Jeff Forringer,General Manager of IntrinsiQ Research, +1-800-565-2279, ext. 101
Web site: http://www.prainternational.com/